P-selectin and sST2 as prognostic biomarkers of cardiovascular events in patients with multiple myeloma following anticancer therapy and severe COVID-19
DOI:
https://doi.org/10.14739/2409-2932.2025.2.329039Keywords:
multiple myeloma, COVID-19, sST2, P-selectin, cardiovascular diseasesAbstract
This study investigates the prognostic value of sST2 and P-selectin as biomarkers for cardiovascular risk in patients with multiple myeloma (MM) who are in remission following anticancer therapy and have experienced severe COVID-19. The topic is of increasing clinical relevance due to the growing incidence of cardiovascular complications in this patient population, highlighting the need for reliable tools for early risk stratification.
The aim of the study was to assess the prognostic significance of sST2 and P-selectin levels as markers of cardiovascular events in multiple myeloma patients after COVID-19.
Materials and methods. The study included 125 patients with MM in partial or complete remission. All participants were followed for 12 months, during which cardiovascular events – including myocardial infarction, stroke, arrhythmias, and heart failure – were recorded. Serum levels of sST2 and P-selectin were measured using ELISA.
Results. Cardiovascular events were observed in 29 (27.1 %) patients. Patients who experienced such events had significantly higher median levels of sST2 (48.6 ng/mL vs. 28.6 ng/mL) and P-selectin (74.1 ng/mL vs. 58.05 ng/mL) compared to those without complications (p < 0.05). ROC analysis demonstrated good diagnostic performance, with an AUC of 0.813 for sST2 and 0.737 for P-selectin. A combined biomarker model (sST2 >28.5 ng/mL and P-selectin >67.0 ng/mL) yielded the highest predictive accuracy.
Conclusions. Elevated serum levels of sST2 and P-selectin are independent predictors of cardiovascular events in patients with MM after severe COVID-19. These findings support the use of a multi-biomarker approach in cardio-oncohematological monitoring to facilitate the early identification of high-risk patients and personalization of therapeutic strategies.
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. doi: https://doi.org/10.3322/caac.21660
Kumar SK, Callander NS, Baljevic M, Cornell RF, Dhodapkar MV, Harrison SJ, et al. NCCN Guidelines Insights: Multiple Myeloma, Version 3.2022. J Natl Compr Canc Netw. 2022;20(1):8-19. doi: https://doi.org/10.6004/jnccn.2022.0002
Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R, et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia. 2014;28(3):525-42. doi: https://doi.org/10.1038/leu.2013.350
Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102(1):14-25. doi: https://doi.org/10.1093/jnci/djp440
Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23(Suppl 7):vii155-66. doi: https://doi.org/10.1093/annonc/mds293
Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417-8. doi: https://doi.org/10.1016/S0140-6736(20)30937-5
Libby P, Lüscher T. COVID-19 is, in the end, an endothelial disease. Eur Heart J. 2020;41(32):3038-44. doi: https://doi.org/10.1093/eurheartj/ehaa623
Mian A, Farag S, Barnes CP, D’Sa S. COVID-19 in haematological patients: A review of current practices and emerging data. Br J Haematol. 2023;201(1):24-37. doi: https://doi.org/10.1111/bjh.18516
De Oliveira LB, Farias LA, Gomes PS, Souza DC, Melo CS, Silva EF, et al. Biomarkers of cardiovascular complications in cancer patients with COVID-19: a systematic review. Crit Rev Oncol Hematol. 2022;179:103822. doi: https://doi.org/10.1016/j.critrevonc.2022.103822
Shi Y, Han H, Ma Y, Zheng J, Xu L, Liu Y, et al. Soluble ST2 correlates with disease severity and predicts outcome in patients with COVID-19. J Allergy Clin Immunol. 2021;147(2):534-6. doi: https://doi.org/10.1016/j.jaci.2020.10.033
Januzzi JL, Mebazaa A, Di Somma S. ST2 and prognosis in acutely decompensated heart failure: the International ST2 Consensus Panel. Am J Cardiol. 2015;115(7 Suppl):26B-31B. doi: https://doi.org/10.1016/j.amjcard.2015.01.037
Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002;106(23):2961-6. doi: https://doi.org/10.1161/01.cir.0000038705.69871.d9
Pascual-Figal DA, Ordoñez-Llanos J, Tornel PL, Vázquez R, Puig T, Valdés M, et al. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J Am Coll Cardiol. 2009;54(23):2174-9. doi: https://doi.org/10.1016/j.jacc.2009.07.041
Bayes-Genis A, de Antonio M, Vila J, Peñafiel J, Galán A, Barallat J, et al. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification. J Am Coll Cardiol. 2014;63(2):158-66. doi: https://doi.org/10.1016/j.jacc.2013.07.087
Michelson AD. P-selectin, a cell adhesion molecule. Thromb Haemost. 1995;74(1):302-8. doi: https://doi.org/10.1055/s-0038-1649432
De Oliveira LB, Farias LA, Gomes PS, Souza DC, Melo CS, Silva EF, et al. Biomarkers of cardiovascular complications in cancer patients with COVID-19: A systematic review. Crit Rev Oncol Hematol. 2022;179:103822. doi: https://doi.org/10.1016/j.critrevonc.2022.103822
Zaid Y, Puhm F, Allaeys I, Naya A, Oudghiri M, Khalki L, et al. Platelets can associate with SARS-CoV-2 RNA and are hyperactivated in COVID-19. Circ Res. 2020;127(11):1404-18. doi: https://doi.org/10.1161/CIRCRESAHA.120.317703
Agrati C, Sacchi A, Bordoni V, Cimini E, Notari S, Grassi G, et al. Elevated P-Selectin in severe COVID-19: Considerations for therapeutic intervention. Clin Transl Sci. 2021;14(5):1800-6. doi: https://doi.org/10.1111/cts.13067
Bayes-Genis A, de Antonio M, Vila J, Peñafiel J, Galán A, Barallat J, et al. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification. J Am Coll Cardiol. 2014;63(2):158-66. doi: https://doi.org/10.1016/j.jacc.2013.07.087
Michelson AD. P-selectin, a cell adhesion molecule. Thromb Haemost. 1995;74(1):302-8. doi: https://doi.org/10.1055/s-0038-1649432
Mian A, Farag S, Barnes CP, D'Sa S. COVID-19 in haematological patients: A review of current practices and emerging data. Br J Haematol. 2023;201(1):24-37. doi: https://doi.org/10.1111/bjh.18563
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 B. B. Samura, M. O. Panasenko, T. O. Samura, I. V. Chorna
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
